ABSTRACT Introduction Sodium Glucose co-Transporter 2 (SGLT2) inhibitors (also known
as 'gliflozins') represent a cornerstone to treat diabetes mellitus. Moreover, recent …

Here we propose that SGLT2 inhibitors (SGLT2i), a class of drugs primarily used to treat type
2 diabetes could also be repositioned as anti-aging senomorphic drugs (agents that prevent …

Background The primary goals during acute heart failure (AHF) hospitalization are
decongestion and guideline-directed medical therapy (GDMT) optimization. Unlike diuretics …

Background Sodium-glucose cotransporter 2 inhibitors are believed to improve cardiac
outcomes due to their osmotic diuretic potential. Objectives The goal of this study was to test …

Chronic infusion of subpressor level of angiotensin II (ANG II) increases the abundance of
Na+ transporters along the distal nephron, balanced by suppression of Na+ transporters …

The main cause of worsening symptoms in acute heart failure (AHF) is pulmonary
congestion. Such congestion may be the consequence of a redistribution of blood volume …

Aims Despite their potential, sodium–glucose cotransporter 2 inhibitors (SGLT2i) have not
been well‐studied in transthyretin amyloid cardiomyopathy (ATTR‐CM) as randomized trials …

For the past decade, clinicians have embraced an oversimplistic explanation for the effect of
sodium-glucose cotransporter 2 inhibitors (SGLT2i) to reduce the risk of heart failure events …

Abstract Sodium-glucose cotransporter 2 (SGLT2)-inhibitors reduce the risk for kidney failure
and are a key component of guideline-directed therapy for chronic kidney disease. While …

A New Age for Secondary Prevention: Optimal Medical Therapy for Stable Ischemic Heart
Disease Among Patients with Diabetes and/or Obesity - Medical Clinics Skip to Main Content …